Table 5.
Incidence of nephrotoxicity and outcomes in the two study groups
| Study group | ||||||
|---|---|---|---|---|---|---|
| Group A (n = 78) | Group B (n = 26) | All (n = 104) | p-value | |||
| Side effects | Nephrotoxicity | n (%) | 5 (6.4) | 6 (23.1) | 11 (10.6) | 0.017* |
| Cure | Clinical Microbiological |
n (%) | 57 (73.1) 39/43 (90.7) |
12 (52.2) 6/8 (75.0) |
69 (68.3) 45 (88.2) |
0.058NS 0.234NS |
| Pitt Bacteremia score | 0–4 > 4 Median (range)§ |
n (%) | 72 (92.3) 6 (7.7) 2.0 (0–7) |
25 (96.2) 1 (3.8) 2.0 (0–8) |
97 (93.3) 7 (6.7) 2.0 (0–8) |
0.677NS 0.498NS 0.895NS |
| CCI score | 0 1–2 3–4 ≥5 Median (range)§ |
n (%) | 13 (16.7) 48 (61.5) 10 (12.8) 7 (9.7) 2.0 (0–6) |
6 (23.1) 16 (61.5) 4 (15.4) 0 2.0 (0–4) |
19 (18.3) 64 (61.5)1 14 (13.5) 7 (6.7) 2.0 (0–6) |
0.413NS 1.0NS 0.740NS 0.165NS |
| Mortality | Day 14 Day 28 |
n (%) | 17 (21.8) 22 (28.2) |
10 (38.5) 12 (46.2) |
27 (26.0) 34 (32.7) |
0.093NS 0.091NS |
§p-value by Mann–Whitney U test; the rest of the p values by Chi-square test or Fisher's exact probability test. p-value < 0.05 is considered to be statistically significant.
*p-value < 0.05, NS, statistically nonsignificant; CCI, charlson comorbidity index